glp-1 drug boom Weight-Loss Sales Slow In May, Mounjaro Still Leads The Pack, #GLP1 #Semaglutide #Mounjaro #Ozempic #Wegovy #WeightLossDrugs #Pharma #IndiaPharma #Healthcare #ObesityTreatment #StockMarket backed formula is designed to support digestion and reduce common discomforts like bloating Why the GLP-1 Boom Has

But emerging treatments like GLP-1 receptor agonists are providing new hope

Gke R, Fehmann HC, Linn T, et al

In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH diagnosis between January 2013 and December 2021 from the TriNetX database to determine how GLP-1 receptor agonist use (n = 1,714) impacts all-cause mortality, respiratory failure, atrial fibrillation, right heart failure and ED visits vs

Introduction Drug shortages of long-acting GLP-1 receptor agonists and dual GLP-1/GIP receptor agonist have emerged unexpectedly and persisted through the first quarter of 2023

Hall, J